Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: therapeutic benefit + no evidence + exubera  Related to the article below (Last Update: 5/12/2008)

WADA Advances Investigations and Enforcement Strategy, Strengthens ...
SFCPressPoint (press release), FL -
This monumental task was performed with the utmost respect for everyone?s views and for achieving a final outcome that would benefit those who have a vested ...
WAFACS Published: No CVD Benefit in Longest-Duration Folic-Acid/B ...
Medscape (subscription) - May 9, 2008
"Even with long duration of treatment, there was no evidence of cardiovascular risk reduction, and we did see a significant reduction in homocysteine. ...
Nventa Announces Additional Positive Immunological Data From HspE7 ...
Canada NewsWire (press release), Canada -
All Patients in Cohort 3 Demonstrated Improvement in T-Cell Responses Further Supporting the Therapeutic Potential of HspE7 >> SAN DIEGO, ...TSE:NVN
New York?s $600 Million Question
National Review Online Blogs, NY -
As it turns out, Lubin?s work was faulted among other things, according to a summary on the CIRM website, for showing ?no evidence of current use or planned ...
Investing in incarceration makes no economic sense
guardian.co.uk, UK - May 6, 2008
There are also savings to be made by investing in effective residential drug treatment and therapeutic programmes. Research commissioned by three charitable ...
Savient Reports Favorable Interim Data from Puricase(R ...
WELT ONLINE, Germany - May 7, 2008
"These interim OLE results provide valuable additional and strongly encouraging evidence of the safety and clinical benefit of pegloticase treatment for ...SVNT

Kent News
'No evidence experimentation will bring cures'
Kent News, United Kingdom - Apr 13, 2008
On the other hand, adult stem cells are being used in patients in clinical trials right now and are already yielding clear evidence of therapeutic efficacy. ...
Homocysteine-Lowering B Vitamin Therapy in Cardiovascular ...
Journal of American Medical Association (subscription), IL - May 6, 2008
8 The first indication of a possible therapeutic benefit of homocysteine lowering was provided by observations in children with homocystinuria, ...

Salem-News.Com
New Federal Report on Marijuana Use is Misleading, Groups Say
Salem-News.Com, OR - May 10, 2008
But this study, like others that benefit the pharmaceutical companies that don't want to compete with marijuana as a medical product, is more of the same, ...
B Vitamins Have No Effect on Cardiovascular Risk in Women
MedPage Today, NJ - May 6, 2008
Explain to interested patients that this study found no benefit for supplementation with folic acid and B vitamins for reducing the risk of cardiovascular ...
Source: Google News

Regimen and Device Compliance: Key Factors in Determining Therapeutic Outcomes -
ML Everard - Journal of Aerosol Medicine, 2006 - liebertonline.com
... The relatively wide therapeutic index of these drugs together ... pa- tients who fail
to derive benefit not because ... It is no longer acceptable for the health care ...

Are Inhaled Systemic Therapies a Viable Option for the Treatment of the Elderly Patient? -
S Allen - Drugs & Aging, 2008 - aging.adisonline.com
... 41] Nevertheless, there have been no studies conducted ... dose result in some therapeutic
benefits because the ... dose range before reaching a therapeutic plateau.[44 ...

Inhaled insulin-a new therapeutic option in the treatment of diabetes mellitus -
JJ Diez, P Iglesias - eop, 2003 - Expert Opinion
... Inhaled insulin, a new therapeutic option in the treatment ... Thus, a clear benefit
is that adjustable premeal doses ... Besides, there have been no reports of major ...

Inhaled human insulin (Exubera?): clinical profile and patient considerations -
AH Barnett, S Bellary - Vascular Health and Risk Management, 2007 - pubmedcentral.nih.gov
... provided further demonstration of a benefit for inhaled ... As for any therapeutic protein,
anti-insulin antibodies may ... trials to date there is no evidence of a ...

Inhaled Human Insulin (Exubera (R)): A Review of its Use in Adult Patients with Diabetes Mellitus. -
C Dunn, MP Curran - Drugs, 2006 - drugs.adisonline.com
... Evidence to date from randomised clinical studies shows ... therapy that delivers the
same therapeutic benefits as an ... Inhaled human insulin is no exception, and ...

[PDF] DRUG NEWS -
THIP REPLACEMENT, S TREATMENT, I INSULIN - nursing2003.com
... STROKE TREATMENT Expanding the therapeutic window ... Minocycline?s benefits were evident
within 1 ... No differences in deaths, myocardial infarction, recurrent ...
-

[PDF] Putting evidence into practice: Outpatient management of type 2 diabetes mellitus
S Feit - unitedhealthfoundation.org
... information of pathophysiologic, prognostic, or therapeutic value to ... on endothelial
dysfunction, and no effect on ... been demonstrated to have benefits or long ...

Therapeutic Information -
A CENTRES, T CONSULTATIONS, D ESTEVE - the Spanish Clinical Pharmacology Society Puerto de la Cruz ( … - Blackwell Synergy
... ASCRIPT, SQL, PHP, HTML), it is no necessary an ... The therapeutic profiles in this
field demonstrate a notable ... reason being the absence of benefits when compared ...

[PDF] New drugs for the treatment of type 2 diabetes -
TA Chowdhury, B Hossain - British Journal of Hospital Medicine, 2007 - bjhm.co.uk
... Figures on cost benefit of inhaled insulin provided by the ... A whole new therapeutic
area ? drugs to treat ... of Hospital Medicine, April 2007, Vol 68, No 4 183 ...

Real-World Trials to Answer Real-World Questions. -
N Freemantle, L Blonde, B Bolinder, RA Gerber, FDR … - PharmacoEconomics, 2005 - pharmacoeconomics.adisonline.com
... and patient are under no obligation to use ... explicitly estimating the potential benefits
of additional ... Diabetes mellitus, treatment; Insulin, therapeutic use. ...

Source: Google Scholar
 
 

Exubera: no evidence available of an additional therapeutic benefit

 
 
IQWiG, The German Institute for Quality and Efficiency in Health Care, has published a comparative review of inhaled Insulin ( Exubera ) versus Insulin administered subcutaneously.

There is currently no evidence available that Exubera in diabetes therapy shows advantages over short-acting human Insulin or Insulin analogues administered subcutaneously.
The available studies do not provide evidence that Exubera would improve the quality of life or treatment satisfaction of diabetes patients in Germany.
However, they do provide indications of disadvantages of Exubera therapy, for example, an increase in severe hypoglycaemia rates.

This is the result of the first Rapid Report produced by the Institute for Quality and Efficiency in Health Care ( Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG ), which was commissioned by the Federal Joint Committee.

For this Rapid Report, outcomes were selected which enabled the comparison of Exubera versus Insulin administered subcutaneously with regard to patient-relevant endpoints.
The endpoints assessed included quality of life, treatment satisfaction, glycaemic control ( changes in HbA1c values ), hypoglycaemia rates, adverse drug effects, and prevention of late complications.

Possible higher risk of severe hypoglycaemia with Exubera therapy

No studies were identified in which inhaled Insulin was compared with Insulin administered subcutaneously in patients with type 2 diabetes, within an identical therapeutic regime.
In the only comparator study identified, the therapeutic regimes investigated were different ( intensified versus conventional Insulin therapy ). In this study, even though the reductions in blood glucose levels were comparable between treatment groups, a tendency towards a higher incidence of severe hypoglycaemia was shown in patients treated with Exubera.

According to current knowledge, Exubera is not a safe alternative, either, for patients with type 1 diabetes. IQWiG's comprehensive literature search only identified two studies in which inhaled Insulin was compared with Insulin administered subcutaneously, within an identical therapeutic regime ( intensified Insulin therapy ). These studies also showed a higher incidence of severe hypoglycaemia in patients treated with Exubera ( even though the reductions in blood glucose levels were comparable between treatment groups ).
<
Long-term risks of Exubera therapy unclear

With regard to adverse drug effects, a higher incidence of cough and formation of insulin antibodies was shown with Exubera therapy. On the basis of the data available, it cannot be excluded that long-term Exubera therapy may lead to pulmonary damage. On the contrary: inconsistent study results and the Summary of Product Characteristics provided by the European Medicines Agency ( EMEA ) in fact indicate a risk potential of Exubera. People who smoke or suffer from pulmonary diseases have so far been excluded from participating in studies on Exubera.

No valid statements on treatment satisfaction and quality of life

Although it is possible to reduce the number of subcutaneous injections with Exubera, they cannot be totally avoided, if the additional administration of basal Insulin is necessary.
Moreover, regular self-measurement of blood glucose levels by skin prick is still necessary. It cannot be inferred from the studies available that this new way of administering Insulin generally improves treatment satisfaction or quality of life in affected patients.
On the one hand, these aspects were not or were only insufficiently described in the available publications, although the respective parameters were investigated.
On the other hand, the relevance of the available data is limited with regard to Germany, as it appears that Exubera was not compared with Insulin administered subcutaneously with pen systems ( which is a widespread type of administration in Germany ).
Instead, it appears that Exubera was compared with insulin administered subcutaneously with syringes for self-filling.

IQWiG does not see its Rapid Report as a conclusive evaluation. IQWiG recommends further evaluations of Exubera and the consideration of previously unpublished data from studies in a next step, provided that the manufacturer supplies them. Furthermore, open issues need to be clarified in an adequately designed randomised intervention study before Exubera is widely prescribed in Germany.


IQWiG is an independent scientific institute that evaluates the benefits and harms of medical services for patients. The Institute investigates which therapeutic and diagnostic measures are possible and meaningful, and relays this information to physicians and patients.

Source: Institute for Quality and Efficiency in Health Care, 2006
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page